— Metastatic Breast Cancer Pipeline Market Companies Involved in Therapeutics Development are AB Science SA,AbbVie Inc.,Acceleron Pharma, Inc.,Acetylon Pharmaceuticals, Inc.,Adgero Biopharmaceuticals, Inc.,Advaxis, Inc.,Advenchen Laboratories, LLC,Alteogen Inc.,Amarna Therapeutics B.V.,Ambrx, Inc.,Amgen Inc.,Aphios Corporation,arGEN-X BV,Aslan Pharmaceuticals Pte. Ltd.,Astellas Pharma Inc.,AstraZeneca Plc,Bayer AG,Beta Pharma, Inc.,Biocon Limited,Bionovis SA,Boehringer Ingelheim GmbH,Bristol-Myers Squibb Company,Campus Technologies Freiburg GmbH,CASI Pharmaceuticals Inc.,Celgene Corporation,Celldex Therapeutics, Inc.,Cellectar Biosciences, Inc.,Celltrion, Inc.,Clovis Oncology, Inc.,Corcept Therapeutics Incorporated,Curadis GmbH,Curaxys, S.L.,Daiichi Sankyo Company, Limited,Deciphera Pharmaceuticals, LLC,DexTech Medical AB,Dompe Farmaceutici S.p.A.,Dr. Reddy's Laboratories Limited,EirGenix Inc.,Eisai Co., Ltd.,Eli Lilly and Company,Ensol Biosciences Inc.,EOS Biosciences, Inc.,Epigen Biosciences, Inc.,Etubics Corporation,Eureka Therapeutics, Inc.,F. Hoffmann-La Roche Ltd.,Gene Techno Science Co., Ltd.,Genelux Corporation,Genentech, Inc.,Genor BioPharma Co., Ltd.,Gilead Sciences, Inc.,Glycotope GmbH,GTx, Inc.,Hanmi Pharmaceuticals, Co. Ltd.,Hetero Drugs Limited,Immune Design Corp.,Immunomedics, Inc.,Immupharma Plc,Imugene Limited,Incyte Corporation,Intas Pharmaceuticals Ltd.,Jiangsu Hengrui Medicine Co., Ltd.,Johnson & Johnson,Kadmon Corporation, LLC,Kancera AB,Karyopharm Therapeutics, Inc.,Laboratoires Pierre Fabre SA,Mabion SA,MacroGenics, Inc.,MandalMed, Inc.,Meabco A/S,MedImmune, LLC,Medivation, Inc.,Merck & Co., Inc.,Merck KGaA,Merrimack Pharmaceuticals, Inc.,Merus B.V.,MetaStat, Inc.,Millennium Pharmaceuticals, Inc.,Morphotek, Inc.,Mycenax Biotech Inc.,NanoCarrier Co., Ltd.,NantKwest, Inc.,Natco Pharma Limited,Nektar Therapeutics,NewLink Genetics Corporation,Nippon Kayaku Co., Ltd.,Northwest Biotherapeutics, Inc.,Novartis AG,Oasmia Pharmaceutical AB,OBI Pharma, Inc.,Oncobiologics, Inc.,Oncolytics Biotech Inc.,OncoMed Pharmaceuticals, Inc.,Oncothyreon Inc.,Ono Pharmaceutical Co., Ltd.,Panacea Pharmaceuticals, Inc.,Paras Biopharmaceuticals Finland Oy,Pfizer Inc.,Pharma Mar, S.A.,PIQUR Therapeutics AG,Plexxikon Inc.,Polaris Pharmaceuticals, Inc.,Polyphor Ltd.,Prescient Therapeutics Limited,Prima BioMed Ltd.,Puma Biotechnology, Inc.,Radius Health, Inc.,Samyang Holdings Corporation,Sanofi,Seattle Genetics, Inc.,Shanghai Henlius Biotech Co., Ltd.,Starpharma Holdings Limited,Sun Pharma Advanced Research Company Ltd.,Syndax Pharmaceuticals, Inc.,Synta Pharmaceuticals Corp.,Synthon Holdings BV,Taiho Pharmaceutical Co., Ltd.,TRACON Pharmaceuticals, Inc.,Transgene Biotek Limited,Vaxil Bio Therapeutics Ltd.,Verastem, Inc.,Vertex Pharmaceuticals Incorporated,VioQuest Pharmaceuticals, Inc.,Wilex AG,WntResearch AB,ZIOPHARM Oncology, Inc.,Zymeworks Inc.
The report provides comprehensive information on the therapeutics under development for Metastatic Breast Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Breast Cancer and features dormant and discontinued projects.
Inquire more about this research report at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=627377
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
• The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer
• The report reviews pipeline therapeutics for Metastatic Breast Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved Metastatic Breast Cancer therapeutics and enlists all their major and minor projects
• The report assesses Metastatic Breast Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news related to pipeline therapeutics for Metastatic Breast Cancer
Complete research report of 1079 pages with TOC is available at http://www.rnrmarketresearch.com/metastatic-breast-cancer-pipeline-review-h1-2016-market-report.html
Reasons to buy
• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of therapeutics under development for Metastatic Breast Cancer
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Metastatic Breast Cancer pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Name: Ritesh Tiwari
Email: Send Email
Organization: RnR Market Research
Address: UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune, Maharashtra 411013, India
Phone: +1888 391 54 41
Release ID: 122508